SYRE Spyre Therapeutics, Inc.
Price Chart
Executive Summary
Spyre Therapeutics held its 2026 Annual Meeting on May 27, 2026, where stockholders approved the amended and restated 2016 Employee Stock Purchase Plan (AR ESPP), adding 1,056,096 shares to the reserve. Director Peter Harwin resigned effective the same date, with no disagreement cited, and the board was reduced from eight to seven members. This is a routine governance filing with no material financial impact.
Actionable Insight
This is a routine post-annual meeting filing with no material trading implications. The ESPP share increase is standard and immaterial relative to market cap. Monitor for any future insider selling patterns following the board resignation, though the departure was explicitly non-disagreement.
Key Facts
- Stockholders approved the Amended and Restated 2016 Employee Stock Purchase Plan, adding 1,056,096 shares to the reserve.
- Director Peter Harwin resigned effective May 27, 2026, with no disagreement with the company.
- Board size reduced from eight to seven directors.
- All three Class I director nominees (Mark McKenna, Cameron Turtle, Laurie Stelzer) were elected.
- KPMG LLP was ratified as independent auditor for fiscal year 2026.
- Say-on-pay proposal received 92.7% support from votes cast (excluding broker non-votes).
Financial Impact
No financial figures reported. The AR ESPP adds 1,056,096 shares to the reserve, representing potential future dilution of approximately 0.7% based on the company's market cap of $6.3B, but no immediate financial impact.
Risk Factors
- Potential future dilution from the 1,056,096 ESPP share reserve, though minimal relative to current market cap.
- Board reduction from eight to seven may concentrate decision-making, but no immediate concern.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001636282-26-000056 |
| Document: syre-20260527.htm | 0001636282-26-000056 |
| Document: 0001636282-26-000056-index-headers.html | 0001636282-26-000056 |
| Document: 0001636282-26-000056-index.html | 0001636282-26-000056 |
| Document: 0001636282-26-000056.txt | 0001636282-26-000056 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
6d ago
|
Insider Cluster
| $78.48 $73.65 | ▼ −6.15% | ▼ −3.56% | $72.00 (−8.26%) |
|
Jun 1, 2026
8d ago
|
8-K
| $69.16 $73.52 | ▲ +6.30% | ▲ +7.00% | $72.00 (+4.11%) |
|
May 29, 2026
11d ago
|
8-K
| $70.54 $69.16 | ▼ −1.96% | ▼ −2.10% | $72.00 (+2.07%) |
|
May 5, 2026
5w ago
|
8-K
| $71.01 $73.00 | ▲ +2.80% | ▲ +1.42% | $72.00 (+1.39%) |
|
May 1, 2026
5w ago
|
Insider Cluster
| $69.42 $69.13 | ▼ −0.42% | ▼ −0.08% | $72.00 (+3.72%) |
|
May 1, 2026
5w ago
|
Insider Cluster
| $69.42 $69.13 | ▼ −0.42% | ▼ −0.08% | $72.00 (+3.72%) |
|
Apr 15, 2026
8w ago
|
Press Release
| $68.99 $69.70 | ▲ +1.03% | ▲ +0.78% | $72.00 (+4.36%) |
|
Apr 13, 2026
8w ago
|
424B5
| $64.01 $68.99 | ▲ +7.78% | ▲ +7.01% | $72.00 (+12.48%) |
|
Apr 13, 2026
8w ago
|
Press Release
| $64.01 $68.99 | ▼ −7.78% | ▼ −7.01% | $72.00 (−12.48%) |
|
Apr 13, 2026
8w ago
|
8-K
| $64.01 $68.99 | ▲ +7.78% | ▲ +7.01% | $72.00 (+12.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access